Key result
While several potential biomarkers for pulmonary arterial hypertension have been investigated, only brain natriuretic peptide is currently recommended for diagnosis and follow-up.
While several potential biomarkers for PAH have been investigated, only brain natriuretic peptide is currently recommended for clinical use.
BNP remains the sole recommended PAH biomarker; leaves open prospective validation of additional candidates.
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature that leads to exercise limitation, right heart failure, and death. There is a need for biomarkers that can aid in early detection, disease surveillance, and treatment monitoring in PAH. Several potential molecules have been investigated; however, only brain natriuretic peptide is currently recommended at diagnosis and for follow-up of PAH patients. This review will focus on potential biomarkers in PAH and will discuss their pathophysiology, prognostic significance, as well as their limitations.
No takes yet. Share an insight, caveat, or question.
Al‐Naamani et al. (2015) conducted a review in Pulmonary arterial hypertension. Circulating biomarkers was evaluated. While several potential biomarkers for pulmonary arterial hypertension have been investigated, only brain natriuretic peptide is currently recommended for diagnosis and follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: